Blood and Lymphatic Cancer-Targets and Therapy

Scope & Guideline

Uncovering Innovative Therapies for Cancer Care

Introduction

Welcome to the Blood and Lymphatic Cancer-Targets and Therapy information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Blood and Lymphatic Cancer-Targets and Therapy, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1179-9889
PublisherDOVE MEDICAL PRESS LTD
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationBLOOD LYMPHAT CANCER / Blood Lymphat. Cancer
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND

Aims and Scopes

The journal 'Blood and Lymphatic Cancer-Targets and Therapy' focuses on the latest advancements and therapeutic strategies in hematological malignancies. It aims to provide a platform for discussing innovative research findings, clinical practices, and emerging therapies that target blood cancers.
  1. Hematological Cancer Research:
    The journal primarily publishes research related to various types of blood cancers, including leukemia, lymphoma, and multiple myeloma, highlighting both basic and clinical research.
  2. Therapeutic Strategies and Innovations:
    A significant focus is placed on novel therapeutic approaches, including targeted therapies, immunotherapies, and precision medicine, aiming to improve patient outcomes in blood malignancies.
  3. Prognostic and Diagnostic Advances:
    The journal emphasizes the development of prognostic models and diagnostic techniques, integrating genomic, transcriptomic, and clinical data to enhance treatment decision-making.
  4. Clinical Management and Guidelines:
    It also encompasses articles discussing clinical management strategies, including treatment protocols, patient management approaches, and the impact of comorbidities on treatment outcomes.
  5. Multidisciplinary Approaches:
    The journal encourages research that reflects interdisciplinary collaboration, incorporating insights from oncology, hematology, immunology, and genetics to advance the understanding and treatment of blood cancers.
The journal has seen several emerging themes that reflect the evolving landscape of research in blood cancers. These trends highlight the journal's responsiveness to new challenges and advancements in the field.
  1. Targeted and Precision Therapies:
    There is a significant increase in publications focused on targeted therapies, including BTK inhibitors, PI3K inhibitors, and CAR T-cell therapies, showcasing a shift towards precision medicine tailored to individual patient profiles.
  2. Prognostic Models Utilizing Genomic Data:
    Recent studies have emphasized the development of prognostic models based on genomic and transcriptomic data, reflecting a trend towards personalized treatment approaches and improved patient stratification.
  3. Interventional Strategies for Refractory Cases:
    Emerging themes include innovative interventional strategies for managing refractory blood cancers, indicating a growing interest in addressing complex clinical challenges and improving treatment outcomes.
  4. Management of Comorbidities in Cancer Patients:
    There is an increasing focus on understanding and managing comorbidities, such as renal impairment in multiple myeloma patients, highlighting the need for comprehensive care in oncology.
  5. Integration of Immunotherapy in Treatment Protocols:
    The integration of immunotherapy, particularly in lymphomas and leukemias, is gaining traction, with more publications exploring the efficacy and safety of these novel approaches in clinical settings.

Declining or Waning

While the journal has a robust focus on various aspects of blood cancers, certain themes appear to be declining in prominence over recent years. These waning scopes reflect shifts in research priorities and clinical practices.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decrease in publications focused solely on traditional chemotherapy regimens, as the field increasingly shifts towards targeted therapies and personalized medicine.
  2. General Reviews without Novel Insights:
    The frequency of general review articles that do not provide novel insights or advancements has diminished, indicating a preference for more focused, data-driven studies that contribute to specific areas of research.
  3. Basic Science Studies:
    Research articles centered on basic science without clear clinical applications or therapeutic implications are becoming less common, as the journal aligns more with translational research that bridges laboratory findings and clinical practice.
  4. Epidemiological Studies:
    Epidemiological studies, while still relevant, are appearing less frequently, possibly due to the journal's growing emphasis on innovative treatment strategies and prognostic models.

Similar Journals

Case Reports in Oncology

Empowering Progress in Oncology Research
Publisher: KARGERISSN: 1662-6575Frequency: 3 issues/year

Case Reports in Oncology is a peer-reviewed journal published by KARGER, dedicated to the dissemination of high-quality case studies and clinical reports in the field of oncology. Since its transition to Open Access in 2008, this Swiss-based journal has aimed to broaden the accessibility of key findings to a global audience of researchers, healthcare professionals, and students. The journal is positioned in the Q3 quartile for oncology, indicating its valuable contribution to the field, while also holding a Scopus rank of 294 out of 404 in Medicine, with a percentile of 27%. However, its open access model ensures that even those outside of traditional academic institutions can engage with critical advancements and novel insights from the oncology community. With a publication span extending from 2010 to 2024, Case Reports in Oncology serves as a crucial platform for sharing unique clinical experiences and innovative treatment strategies, ultimately enriching the practice and study of oncology.

Iraqi Journal of Hematology

Shaping the Future of Hematological Practices
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2072-8069Frequency: 2 issues/year

Iraqi Journal of Hematology is a prominent peer-reviewed open-access journal dedicated to advancing the field of hematology. Published by Wolters Kluwer Medknow Publications, this journal provides a platform for researchers, professionals, and students to share cutting-edge findings and developments in various aspects of hematology, including blood diseases, diagnostics, and innovative treatments. Since its transition to open access in 2016, the journal has significantly increased its reach, allowing for wider dissemination of critical research to a global audience. With an ISSN of 2072-8069 and an E-ISSN of 2543-2702, the Iraqi Journal of Hematology strives to adhere to the highest scholarly standards and plays a vital role in the ongoing discourse in hematological research. Researchers are encouraged to contribute to this essential resource for the scientific community, contributing to the advancement of knowledge that ultimately improves patient care and treatment outcomes.

Blood Cancer Journal

Elevating standards in blood cancer studies.
Publisher: SPRINGERNATUREISSN: 2044-5385Frequency: 1 issue/year

Blood Cancer Journal, published by SPRINGERNATURE, is a leading open-access journal that has been at the forefront of hematology and oncology research since its inception in 2011. With an impressive impact factor and a commitment to disseminating high-quality research, it holds a prestigious Q1 ranking in both hematology and oncology categories as of 2023. The journal is dedicated to publishing innovative studies, comprehensive reviews, and insightful commentaries that advance our understanding of blood cancers, making it an essential resource for researchers, healthcare professionals, and students in the field. Its open-access model ensures that groundbreaking research is accessible to a global audience, promoting collaborative efforts to enhance treatment methodologies and patient outcomes. With a strong reputation illustrated by its Scopus rankings—8th in hematology and 30th in oncology—Blood Cancer Journal exemplifies excellence and leadership in the ever-evolving landscape of cancer research.

INTERNATIONAL JOURNAL OF HEMATOLOGY

Advancing the Science of Blood Health
Publisher: SPRINGER JAPAN KKISSN: 0925-5710Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

Blood Science

Connecting Researchers to Breakthroughs in Hematology
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2543-6368Frequency:

Blood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.

EUROPEAN JOURNAL OF HAEMATOLOGY

Exploring the Frontiers of Hematological Science
Publisher: WILEYISSN: 0902-4441Frequency: 12 issues/year

EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.

Leukemia Research Reports

Unlocking the future of leukemia treatment.
Publisher: ELSEVIER ADVANCED TECHNOLOGYISSN: 2213-0489Frequency: 2 issues/year

Leukemia Research Reports, published by Elsevier Advanced Technology, is a prominent open-access journal dedicated to the latest advancements in the field of hematology and oncology. Since its launch in 2012, this journal has been a vital resource for researchers, healthcare professionals, and students aiming to disseminate and access high-quality research articles focused on various aspects of leukemia and related blood disorders. With an impact factor indicative of its significance in the field, Leukemia Research Reports currently holds a Q3 quartile ranking in both Hematology and Oncology, and is included in key databases such as Scopus. The journal not only embraces a commitment to open access, ensuring that research is freely available, but also actively promotes collaborations that strive to enhance our understanding and treatment of leukemia. Based in the United Kingdom, this journal continues to play a crucial role in fostering innovation and knowledge sharing within the medical community.

GEMATOLOGIYA I TRANSFUZIOLOGIYA

Connecting Scholars to the Heart of Medical Science
Publisher: MINISTERSTVO ZDRAVOOKHRANENIYAISSN: 0234-5730Frequency: 4 issues/year

GEMATOLOGIYA I TRANSFUZIOLOGIYA is an esteemed journal published by the MINISTERSTVO ZDRAVOOKHRANENIYA in the Russian Federation, focusing on the vital fields of hematology and transfusion medicine. With a rich history dating back to its inception in 1983, the journal plays a significant role in disseminating critical research and advancements in these areas, particularly relevant given the evolving landscape of medical science. As a recognized publication, it is indexed in Scopus and holds a Q4 category ranking in Hematology for 2023, reflecting its niche but important contributions to the field. Researchers, healthcare professionals, and students can look forward to a variety of peer-reviewed articles that not only address contemporary issues but also pave the way for innovative practices in hematology. Although it does not currently offer open access, the journal remains a valuable resource for those seeking to stay informed about the latest findings and developments.

ANNALS OF HEMATOLOGY

Fostering interdisciplinary dialogue in hematology and medicine.
Publisher: SPRINGERISSN: 0939-5555Frequency: 12 issues/year

ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.

PEDIATRIC HEMATOLOGY AND ONCOLOGY

Fostering dialogue in the realm of child health and treatment.
Publisher: TAYLOR & FRANCIS INCISSN: 0888-0018Frequency: 8 issues/year

Pediatric Hematology and Oncology, published by Taylor & Francis Inc, serves as a vital platform dedicated to the fields of hematology, oncology, and pediatrics, providing a comprehensive avenue for the dissemination of scholarly research and clinical advancements. With an ISSN of 0888-0018 and an E-ISSN of 1521-0669, this journal has successfully converged its expertise over the years from 1984 to 2024. Ranked in the Q3 category for Hematology and Oncology, alongside a Q2 ranking in Pediatrics, Perinatology, and Child Health (2023), it engages a diverse readership comprising researchers, healthcare professionals, and students eager to explore groundbreaking studies in child health and treatment methodologies. While it currently does not offer Open Access options, the journal is widely cited and recognized, particularly in its specialized fields, fostering a rich environment for dialogue and innovation in the management of pediatric hematological and oncological disorders. The journal is based in the United Kingdom at 530 Walnut Street, Ste 850, Philadelphia, PA 19106, making it an essential resource for those pursuing excellence in pediatric medical research.